Status: Not yet recruiting
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody (\[89Zr\]DFO-YS5) in participants with nerve sheath tumor, bladder cancer, or advanced solid tumor neoplasms.
Participants needed: 40
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Robert Flavell, MD, PhDUpdated: Jun 24, 2026Locations: 1
Eligibility criteria
Histological or cytological confirmation of malignant peripheral nerve sheath tu... [+11]
Individuals with a contraindication to PET-CT imaging (e.g., severe claustrophob... [+3]